Cipla Ltd. Share Price

Overview

Cipla Ltd. share price is currently ₹1,402.05, up by ₹0.96 (0.07%) from its previous closing price of ₹1,401.09. The share price has gained 5.9% over the past month and declined -7.82% over the past year. The stock's 52-week low and high are ₹1,146.55 and ₹1,516.53, respectively. Cipla Ltd. has a market capitalisation of ₹ 1,14,312.12 Cr. The share price was last updated on 20 Nov 2026, 03:52 PM IST.

Cipla Ltd.
Cipla Ltd.
CIPLA
 ₹0.00
 ₹0.96
0.07%
Healthcare
 ₹0.00(%)1D

Updated: 20 Nov 2026, 03:52:37 pm IST

Market Data

Open Price

 ₹1,405.54

Prev. Close

 ₹1,401.09
 ₹1,388.11

Day Low

 ₹1,415.13

Day High

 ₹1,146.55

52 Week Low

 ₹1,516.53

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

39.10

Sector PE

46.21

PB Ratio

3.30

Sector PB

6.06

EPS

35.86

Dividend Yield

1.06

Today's Volume

1.867 M

5 Day Avg. Volume

1.864 M

PEG Ratio

-1.48

Market Cap.

₹ 1,14,312.12 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 650% at ₹13/Share
05-Jun-202605-Jun-2026
DividendsSpecial Dividend of 150% at ₹3/Share
27-Jun-202527-Jun-2025
DividendsFinal Dividend of 650% at ₹13/Share
27-Jun-202527-Jun-2025

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
HDFC Flexi Cap Fund - Growth1.99 Cr
1.99 Cr
no change
Parag Parikh Flexi Cap Fund - Regular Plan - Growth1.44 Cr
1.44 Cr
no change
SBI Nifty 50 ETF1.09 Cr
1.09 Cr
(0.15%)
ICICI Prudential Value Fund - Growth57.31 Lac
57.31 Lac
no change
SBI ELSS Tax Saver Fund - Regular Plan - IDCW47.57 Lac
47.57 Lac
no change

About Cipla Ltd. 👋

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Arthavrksh

Arthavrksh

19 Nov • 8:06 AM · SEBI-Registered Analyst

Nifty Pivot 25,240-25,260; SBIN, Cipla Lead

Pre-open cues are weak, with GIFT Nifty around 65 points lower, and the Dow Jones fell about 561 points (1.11%) yesterday. On Wednesday, Nifty opened with a gap-down, tested the 25,269 and 25,150 levels, took support near 25,150 and recovered to close near 25,220. The pivot cluster for the day is 25,240-25,260, which is also where the falling trendline sits. The 30-minute RSI at about 45 is below the midline, so momentum is slightly weak, and the negative divergence from the recent high is still visible. Resistance levels are 25,365 and 25,500. Supports are 25,115 and 25,000. Sustained trade above 25,260 would bring 25,365 into view, while staying below the cluster keeps 25,115 and 25,000 in focus. The top Nifty gainers yesterday were SBIN (+2.38%), Cipla (+2.09%) and Tata Consumer (+1.66%), which are worth observing today. The first half-hour of trade will be important. When price sits below a pivot that coincides with a trendline, that zone acts as resistance; sustained trade above it is what would improve the picture. Disclaimer: This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

See More
Neha Gupta

Neha Gupta

19 Nov • 2:15 AM · SEBI-Registered Analyst

Cipla Gains 2%: USFDA Clears InvaGen New York Plant

💊 CIPLA rose about 2.1% to ₹1,417.50 on 18 Nov 2026, even as the Nifty fell 0.63% on profit booking. The trigger: the USFDA has classified the recent inspection of its US subsidiary InvaGen's New York facility as "No Action Indicated" (NAI). What this opinion covers: ✅ The routine cGMP inspection at InvaGen's Hauppauge, Long Island plant ran from 19 to 22 Oct 2026 and ended with zero Form 483 observations ✅ NAI is the cleanest USFDA outcome: no objectionable conditions were found ✅ InvaGen is a wholly owned subsidiary and part of Cipla's US generics supply base ✅ Pharma was one of only 3 of 16 sectoral indices to close in the green on a weak day ✅ What to track next: new US product approvals, compliance status of other plants, and the US sales trend in upcoming quarters Why it matters: for Indian pharma companies, a clean regulatory record at US plants supports timely product launches and lowers compliance risk. Regulatory outcomes are one input; valuation, pricing pressure and the product pipeline matter too. 💬 Do you check USFDA inspection outcomes before studying a pharma stock? Share your view in the comments! 📲 For daily market notes, search "Neha Gupta SEBI RA" on Telegram and join the FREE channel. Neha Gupta | SEBI Registered Research Analyst | Reg. No. INH000016542 ⚠️ Disclaimer: This content is for educational purposes only and is not investment advice or a buy/sell recommendation. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.

See More
Vimal K

Vimal K

18 Nov • 11:49 PM · SEBI-Registered Analyst

Nifty Outlook for 19-Nov-2026 Looks Range Bound

For Thursday, 19 November 2026, the Nifty 50 carries a cautious to range-bound outlook after slipping 0.63% (-159.45 points) on Wednesday to close at 25,227.95. The Daily MACD Histogram above zero and Hourly MACD Histogram below zero indicates a tug of war between buyers and sellers. The Daily RSI 14 at 72.59 and Hourly RSI 14 at 50.09 indicates a bullish trend. But, the Daily RSI 14 indicates overbought zone, and we may see some profit booking at higher levels. Thus, the overall trend of Nifty looks to be in a range, and the markets might move either side. Buy on dips and sell on rise would be the best strategy to deploy for today’s market considering the overall trend of Nifty. We may expect a change in trend only if the price sustains below the support level or above the resistance level. I have provided Nifty Spot resistance and support levels which would help you learn in taking informed trading decisions using these levels and understand how support and resistance levels work in financial markets. Nifty Spot Resistance 1 - 25365 Resistance 2 - 25405 Support 1 - 25105 Support 2 - 25070 Happy Learning, Happy Trading and have a wonderful day Top Gainers : SBIN, CIPLA, TATACONSUM. Top Losers : TITAN, HDFCLIFE, HINDALCO. SBIN

See More
Anish Rai

Anish Rai

18 Nov • 4:00 PM · SEBI-Registered Analyst

Closing Bell: Sensex Sheds 500 Pts, Nifty Slips Below 25,250

Indian stock market benchmarks concluded Wednesday’s session, November 18, with significant losses, as the Sensex shed nearly 500 points and the Nifty closed below the 25,250 level. Selling activity intensified across multiple sectors, with Consumer Durables and Metal stocks bearing the brunt of the decline. Top Nifty Losers: Titan Company, HINDALCO Industries, HDFC Life, BSE Limited and Bajaj Finance were among the biggest underperformers on the Nifty 50, facing considerable selling pressure during the trading session. Top Nifty Gainers: In contrast, SBI, Cipla, Tata Consumer Products, ITC and Apollo Hospitals featured among the top-performing Nifty constituents, managing to post gains despite the broader market weakness. Sectoral Trends: The Consumer Durables index recorded the steepest decline, falling nearly 3%, followed by the Metal index, which dropped around 2%. Auto and IT indices also weakened by approximately 1% each. Meanwhile, Media, Pharma and PSU Bank indices offered some relief, registering gains of nearly 0.5% apiece. Broader Market Performance: Selling pressure was also evident in the broader market space. The Nifty Midcap index declined around 1.6%, while the Nifty Smallcap index edged lower by 0.4%, reflecting weakness across different market segments. Market Summary: Domestic equity markets witnessed widespread profit booking, with substantial losses in Consumer Durables and Metal shares dragging the benchmark indices lower. Despite some resilience in select banking, pharmaceutical and FMCG stocks, overall market sentiment remained subdued. #ClosingBell #SensexToday #Nifty50 #StockMarketToday #IndianStockMarket #ShareMarketNews Disclaimer: Investment in securities market are subject to market risks. Read all related documents carefully before investing.

See More
Capital Investo Research

Capital Investo Research

18 Nov • 3:48 PM · SEBI-Registered Analyst

Closing Bell:Sensex Slides 500 Pts, Nifty Falls Below 25,250

Indian equity benchmarks ended Wednesday’s trading session, November 18, on a weak footing, with the Sensex declining around 500 points and the Nifty slipping below the 25,250 mark. Selling pressure remained visible across several sectors, particularly Consumer Durables and Metal stocks. Top Nifty Losers: Titan Company, Hindalco Industries, HDFC Life, BSE Limited and Bajaj Finance featured among the major laggards on the Nifty 50 index, witnessing notable selling activity during the session. Top Nifty Gainers: On the other hand, SBI, Cipla, Tata Consumer Products, ITC and Apollo Hospitals emerged among the leading gainers, outperforming the broader market. Sectoral Performance: Consumer Durables stocks witnessed the sharpest correction, with the Nifty Consumer Durables index declining nearly 3%. The Nifty Metal index dropped around 2%, while Auto and IT indices registered losses of approximately 1% each. Conversely, Media, Pharma and PSU Bank indices managed to remain in positive territory, advancing around 0.5% each. Broader Market Update: Weakness extended to mid- and small-cap stocks as well. The Nifty Midcap index declined approximately 1.6%, while the Nifty Smallcap index slipped 0.4%, indicating selling pressure beyond frontline stocks. Market Wrap-Up: Domestic equity markets remained under pressure throughout the session, with heavy selling in Consumer Durables and Metal counters weighing on benchmark indices. Although select stocks from banking, pharmaceutical and FMCG segments showed resilience, broader market sentiment remained cautious. #ClosingBell #SensexToday #Nifty50 #StockMarketToday #IndianStockMarket #ShareMarketNews Disclaimer: Investment in securities market are subject to market risks.

See More
Finkhoz Roboadvisory Services

Finkhoz Roboadvisory Services

18 Nov • 1:56 PM · SEBI-Registered Analyst

Cipla rises 3% as USFDA clears InvaGen plant

CIPLA Limited (CIPLA) rose as much as 3% to a day high of ₹1,435 on November 18, after the US Food and Drug Administration (USFDA) gave a clean chit to its InvaGen plant in New York. The stock traded at ₹1,432.80 at 11:37 AM, up 3.23% from the previous close of ₹1,388. Cipla disclosed the update late on November 17. The USFDA classified InvaGen’s Hauppauge facility on Long Island as No Action Indicated (NAI), the best possible outcome of an inspection. The inspection took place from October 19 to 22, and the report formally closes an earlier inspection at the site. InvaGen is Cipla’s wholly owned US subsidiary. A clean inspection removes a regulatory overhang. With NAI status, the plant can keep supplying the US market and support new product approvals without the risk of warning letters or import restrictions. For a company with a large US business, a compliant manufacturing base is essential. The clearance does not fix the bigger US problem. North America revenue in Q2 was $172 million, up $10 million from the previous quarter but 19% lower than a year ago. A clean plant helps protect existing business, but growth depends on new product launches. Investors will want to see whether Cipla can build a US pipeline strong enough to reverse the yearly decline. Investors should watch new US product approvals and launches, North America revenue in coming quarters, other pending USFDA inspections, and India business growth. The key question is whether Cipla can turn a clean regulatory record into renewed US growth. Disclosure: I do not hold any position in Cipla Limited. This post is for informational purposes only and is not investment advice.

See More

News & Events

Frequently Asked Questions

What is the share price of Cipla Ltd.?

What is the market cap of Cipla Ltd.?

Should I buy Cipla Ltd. stock now?

What is the 52 week high and low of Cipla Ltd.?

Is the Cipla Ltd. stock good to buy?

Is Cipla Ltd. a good buy for the long term?

Is Cipla Ltd. overvalued or undervalued?

What is the PE and PB ratio of Cipla Ltd.?

Start Now